Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 20/20 | 0.45 |
| ▸ | NTRK3 | Q16288 | 9/20 | 0.45 |
| ▸ | NTRK2 | Q16620 | 8/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27060205 | 0.85 | NTRK1 (0.47) | NTRK1NTRK3NTRK2 | |
| SCHEMBL27060264 | 0.85 | NTRK1 (0.50) | NTRK1NTRK3NTRK2 | |
| SCHEMBL22646665 | 0.84 | NTRK1 (0.47) | NTRK1NTRK3NTRK2 | |
| SCHEMBL27060206 | 0.81 | NTRK1 (0.50) | NTRK1NTRK3NTRK2 | |
| SCHEMBL27060133 | 0.80 | NTRK1 (0.47) | NTRK1NTRK3NTRK2 | |
| SCHEMBL27060235 | 0.80 | NTRK1 (0.43) | NTRK1NTRK3NTRK2 | |
| SCHEMBL27060302 | 0.80 | NTRK1 (0.49) | NTRK1NTRK3NTRK2 | |
| SCHEMBL27060250 | 0.80 | NTRK1 (0.47) | NTRK1NTRK3NTRK2 | |
| SCHEMBL27060204 | 0.80 | NTRK1 (0.49) | NTRK1NTRK3NTRK2 | |
| SCHEMBL27060231 | 0.75 | NTRK1 (0.52) | NTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025908-A1 | COMPOUND USED AS KINASE INHIBITOR AND USE THEREOF | TYK MEDICINES, INC. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025908-A1 | COMPOUND USED AS KINASE INHIBITOR AND USE THEREOF | TYK MEDICINES, INC. (CN) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025908-A1 | COMPOUND USED AS KINASE INHIBITOR AND USE THEREOF | ROS1, ALK, RET | NTRK1 15/4885NTRK3 36/4885NTRK2 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.